Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: James N Ingle Daniel W Visscher Edith A. Perez Vera J Suman |
| Publication date | December 1, 2005 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |